Medicine profile
Tirzepatide
Once-weekly dual GIP and GLP-1 receptor agonist marketed for type 2 diabetes and weight management; Zepbound in the US also carries an obstructive sleep apnoea indication.
- Generic name
- Tirzepatide
- Also known as
- Mounjaro, Zepbound
- Sponsor and licensing
- Eli Lilly (originator)
- Mechanism
- GIP and GLP-1 receptor agonist
- Molecular type
- Peptide (mechanism and molecular type are recorded separately: GLP-1 activity does not make a medicine a peptide)
Brands, routes and formulations
Zepbound
subcutaneous 路 once-weekly injection 路 United States brand
- United States: Chronic weight management (8 Nov 2023)
- United States: Obstructive sleep apnoea (20 Dec 2024)
Mounjaro
subcutaneous 路 once-weekly injection
- United States: Type 2 diabetes (glycaemic control) (13 May 2022)
Regulatory status by jurisdiction
Authorisation, launch and funded access are three different things and are shown separately. "Not recorded" means GLPInfo has not verified an event, not that nothing has happened.
| United States (FDA) | United Kingdom (MHRA) | European Union (EMA / EC) | |
|---|---|---|---|
| Regulatory authorisation | 13 May 2022 路 MounjaroType 2 diabetes (glycaemic control)8 Nov 2023 路 ZepboundChronic weight management20 Dec 2024 路 ZepboundObstructive sleep apnoea | Not recorded | Not recorded |
| Commercial launch | Not recorded | Not recorded | Not recorded |
| Funded access | Not recorded | Not recorded | Not recorded |
Development timeline
Tirzepatide
Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Select a marker to open its record in the pipeline view, which has the detail panel and the accessible list.
Next milestone and forecast rationale
No forecast is published for Tirzepatide. Approved medicines only carry forecasts for new indications or jurisdictions when a filing anchor exists.
Trial evidence
| Trial | Phase | Population | Duration | Results |
|---|---|---|---|---|
| SURMOUNT-1Eli Lilly 路 subcutaneous, once weekly | 3 | 2,539 adults without type 2 diabetes; BMI 30 or more, or 27 or more with at least one weight-related condition | 72 weeks | On file from the research workbook; withheld until the primary publication or registry record is attached. |
| SURPASS-2Eli Lilly 路 subcutaneous, once weekly | 3 | 1,879 adults with type 2 diabetes inadequately controlled on metformin | 40 weeks | On file from the research workbook; withheld until the primary publication or registry record is attached. |
GLPInfo does not rank unrelated trials against each other or quote "weight loss per week": populations, durations and methods differ and weight change is not linear. Results appear here per trial and dose arm, with comparator, endpoint and source, once cited.
Known limitations and official labels
This profile is assembled from the regulatory records and sponsor statements GLPInfo has verified; it is not a complete review of Tirzepatide. The current official label in each jurisdiction is the authority on indications, populations and safety. Official records read for this profile: Drugs@FDA: NDA 217806 Zepbound (tirzepatide) approval history; Drugs@FDA: NDA 215866 Mounjaro (tirzepatide) approval history.
Review date and correction history
Records last checked 13 Sep 2026. No corrections have been made to the records on this profile; every record is at version 1. Report a correction.
Related news
No news articles yet for Tirzepatide.